1. Home
  2. CRGX vs SPTN Comparison

CRGX vs SPTN Comparison

Compare CRGX & SPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRGX
  • SPTN
  • Stock Information
  • Founded
  • CRGX 2021
  • SPTN 1917
  • Country
  • CRGX United States
  • SPTN United States
  • Employees
  • CRGX N/A
  • SPTN N/A
  • Industry
  • CRGX
  • SPTN Food Distributors
  • Sector
  • CRGX
  • SPTN Consumer Discretionary
  • Exchange
  • CRGX Nasdaq
  • SPTN Nasdaq
  • Market Cap
  • CRGX 190.0M
  • SPTN 596.4M
  • IPO Year
  • CRGX 2023
  • SPTN N/A
  • Fundamental
  • Price
  • CRGX $4.59
  • SPTN $26.57
  • Analyst Decision
  • CRGX Hold
  • SPTN Hold
  • Analyst Count
  • CRGX 7
  • SPTN 1
  • Target Price
  • CRGX $5.33
  • SPTN $26.90
  • AVG Volume (30 Days)
  • CRGX 1.9M
  • SPTN 1.4M
  • Earning Date
  • CRGX 08-11-2025
  • SPTN 08-14-2025
  • Dividend Yield
  • CRGX N/A
  • SPTN 3.28%
  • EPS Growth
  • CRGX N/A
  • SPTN N/A
  • EPS
  • CRGX N/A
  • SPTN N/A
  • Revenue
  • CRGX N/A
  • SPTN $9,652,685,000.00
  • Revenue This Year
  • CRGX $57.81
  • SPTN $6.00
  • Revenue Next Year
  • CRGX N/A
  • SPTN N/A
  • P/E Ratio
  • CRGX N/A
  • SPTN N/A
  • Revenue Growth
  • CRGX N/A
  • SPTN 0.26
  • 52 Week Low
  • CRGX $3.00
  • SPTN $17.30
  • 52 Week High
  • CRGX $25.45
  • SPTN $26.69
  • Technical
  • Relative Strength Index (RSI)
  • CRGX 61.56
  • SPTN 77.47
  • Support Level
  • CRGX $4.32
  • SPTN $26.37
  • Resistance Level
  • CRGX $4.63
  • SPTN $26.58
  • Average True Range (ATR)
  • CRGX 0.16
  • SPTN 0.13
  • MACD
  • CRGX 0.04
  • SPTN 0.07
  • Stochastic Oscillator
  • CRGX 76.44
  • SPTN 72.09

About CRGX CARGO Therapeutics Inc.

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.

About SPTN SpartanNash Company

SpartanNash Co is a food solutions company that delivers the ingredients. Its principal business activities include, distributing grocery products to a diverse group of independent and chain retailers, its corporate-owned retail stores, and U.S. military commissaries and exchanges; as well as operating a fresh produce distribution network and the Our Family private label brand. The company operates in two segments: Retail and Wholesale. Majority of the revenue is earned from its Wholesale segment which uses a multi-channel sales approach to distribute national brand and private brand products to independent retailers, national accounts, food service distributors, e-commerce providers, and the Company's corporate owned retail stores.

Share on Social Networks: